Aurora kinase A (AURKA) mRNA expression was identified as a biomarker of PP2A-dependent growth factor activation, and was used to classify breast cancer cases into a novel therapeutic class of tumors with predicted susceptibility to the restoration of PP2A activity using FTY720 (unpublished data). This evidence concerns the gene AURKA and breast carcinoma.